4/6/2023 0 Comments Keynote 355The combination of pembrolizumab plus chemotherapy was granted Breakthrough Therapy designation by the FDA for the neoadjuvant treatment of patients with high-risk, early-stage triple-negative breast cancer. Numerous trials in the neoadjuvant and adjuvant settings have shown the benefits of pembrolizumab as monotherapy and in combination with chemotherapy in PD-L1–positive triple-negative breast cancer. Food and Drug Administration (FDA) for the treatment of patients with locally recurrent, unresectable, or metastatic triple-negative breast cancer whose tumors express PD-L1 ,” she stated. Based on the progression-free survival results from KEYNOTE-355, the combination of pembrolizumab and chemotherapy was granted accelerated approval by the U.S. “These findings provide further support for the addition of pembrolizumab to standard chemotherapy for first-line metastatic triple-negative breast cancer. Rugo presented additional endpoints from KEYNOTE-355 at the 2020 San Antonio Breast Cancer Symposium. “A subgroup analysis showed that pembrolizumab plus chemotherapy improved progression-free survival regardless of the chemotherapy partner.” Dr. Rugo, MD, Professor and Medical Director of Breast Oncology, University of California San Francisco. A trend toward improved progression-free survival was observed with PD-L1 enrichment,” said lead author Hope S. “Pembrolizumab plus chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone for first-line treatment of PD-L1–positive metastatic triple-negative breast cancer. ![]() ![]() 1 Progression-free survival was significantly improved with pembrolizumab plus chemotherapy in PD-L1–positive triple-negative breast cancer (ie, combined positive score ≥ 10) regardless of the chemotherapy regimen used in the trial. Pembrolizumab plus chemotherapy improved progression-free survival vs chemotherapy alone as first-line treatment of advanced or metastatic triple-negative breast cancer, according to the results of KEYNOTE-355.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |